EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

RemeGen Co. Ltd (REGMF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of RemeGen Co. Ltd $3.01, price $9.96, upside -69.8%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · Home China

RC RemeGen Co. Ltd logo Some data Sep 24, 2026

RemeGen Co. Ltd

REGMF · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $3.01 · Strongly overvalued (−69.8%)
!Quality 58/100
!Mixed Growth (revenue 3y +60.4 %/yr)
✓Highly profitable · 38.2% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (5/13)
!Moderate moat 58/100
!Insider activity 45/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range $2.10 to $7.77
!Weak on dividend: 21 out of 100
Watch RemeGen Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$15.63 $1.50 Fair Value $3.01 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $1.50 – $15.63 · fair‑value band $2.10 – $7.77 · the $9.96 price screens above the $3.01 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow RemeGen Co. in your weekly email

Every Wednesday you see whether RemeGen Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States.

Show more

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.

Stock analysis

RemeGen Co. Ltd (REGMF) currently trades at $9.96, while our model-based Fair Value estimate is $3.01, 69.8% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $8.72 per share, and 0 of the 15 models we run sit above the $9.96 price.

Bear case: the Economic Profit group reads lowest at $0.4500, and 15 of the 15 models stay below the price. Evidence for this calculation is medium.

Scenario range: $2.10 (bear) to $7.77 (bull), the price of $9.96 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

RemeGen Co. Ltd reported revenue of 3.2B CNY in FY2025 versus 1.4B CNY in FY2021, a compound +22.1%/yr. Reported net income was 690M CNY in FY2025, compounding +25.7%/yr from FY2021.

Key figures

Market cap $6.8B · P/E ratio 63.4 · P/S ratio 13.8 · EPS (TTM) $0.1900 · Dividend yield 1.0% · Net margin 21.8% · Return on equity 45.3% · Return on assets (EBIT) −12.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (medium confidence).

What moves the price

The share trades about 22% below its 52-week high and 97% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −70%, REGMF screens richer than that median.

Fair Value models

Bear $2.10 Fair Value $3.01 Bull $7.77
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1437 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV $0.4100 $0.4500 $0.4900 74
Residual Income $1.20 $1.59 $2.80 71
ROIC Compounder $0.4100 $0.4500 $0.4900 70
All 15 models by family
DCF Models
Owner Earnings $3.63 $7.90 $16.53 68
Earnings-Based
Graham-Dodd $1.28 $8.90 $12.48 61
Lynch FV $4.60 $6.57 $8.54 59
PEG = 1.0 $4.60 $6.57 $8.54 55
EPV $0.4100 $0.4500 $0.4900 74
Multiples
P/E Multiple $3.10 $4.13 $5.16 63
P/S Multiple $2.26 $3.01 $3.77 58
P/B Multiple $2.39 $3.19 $3.99 55
EV/EBIT $0.5700 $0.7100 $0.8600 66
EV/EBITDA $1.38 $1.80 $2.21 67
EV/Revenue $0.4400 $0.5700 $0.7100 54
Asset-Based
NCAV (Graham) $0.4900 $0.6600 $0.9800 54
Economic Profit
Residual Income $1.20 $1.59 $2.80 71
ROIC Compounder $0.4100 $0.4500 $0.4900 70
Growth Earnings
Growth-Adj P/E $6.10 $8.72 $11.33 65

Open the full fair value analysis →

Notify me when REGMF reaches fair value

Put REGMF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 53 · Market factors (momentum, volatility) 61

Profitability 62
Margins and returns on capital today
Quality Growth 91
Are margins and returns improving?
Cashflow 5
Earnings quality: real cash, not paper profit
Fin. Strength 42
Balance sheet, leverage, solvency risk
Investment 82
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 57
Price trend over the last 3–12 months (market factor)
52W Momentum 82
Distance to the 52-week high (market factor)
Net Issuance 65
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 59/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+85.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+60.4%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+123.6%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+18.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+17.3%
Dividend (yield on the price)1.0%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−107,924% → 4%

REGMF screens overvalued: fair value 70% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare RemeGen Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 58 · Top 25%
Fair Value upside −67.7% · Below median
Profitability
Return on equity (TTM) 45.3% · Top 25%
Return on assets 3.4% · Top 25%
Net margin (TTM) 38.2% · Top 25%
Operating margin (TTM) −3.4% · Below median
Growth and dividend
Revenue growth 24.8% · Above median
Dividend yield (TTM) 1.0% · Below median
Balance sheet
Debt / equity 0.20× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 63.4× · Priciest 25%
P/B 12.60× · Priciest 25%
P/S (TTM) 13.46× · Priciest 25%
EV/EBITDA 75.2× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)90 · sector 97
DIVIDEND (yield)21 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

RemeGen Co. Ltd · Fair Value
$3.01 −70%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "RemeGen Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/REGMF

Frequently asked questions

Is RemeGen Co. Ltd (REGMF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $3.01 versus the last price from Sep 25, 2026 of $9.96, about −70% upside (overvalued).
What is the fair value of REGMF?
Our model-based fair value for RemeGen Co. Ltd is $3.01 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $9.96.
What is the quality score of REGMF?
RemeGen Co. Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RemeGen Co. Ltd (REGMF)?
Our model-based price target is the fair value of $3.01 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario $2.10, optimistic scenario $7.77. It is a calculation from audited fundamentals, not an analyst target.
What is the RemeGen Co. Ltd stock forecast for 2026?
Our models put fair value at $3.01, about −70% upside versus the last price from Sep 25, 2026 of $9.96 (overvalued). Cautious scenario $2.10, optimistic scenario $7.77. The calculation is refreshed regularly with new filings.
What is the revenue of RemeGen Co. Ltd (REGMF)?
RemeGen Co. Ltd reported trailing-twelve-month revenue of about 3.4B CNY (latest available figure, as of Sep 24, 2026).
Does RemeGen Co. Ltd pay a dividend?
RemeGen Co. Ltd currently shows a dividend yield of about 1.03% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of RemeGen Co. Ltd (REGMF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RemeGen Co. Ltd it is $3.01 per share (as of Sep 24, 2026), against a price of $9.96. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is RemeGen Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, REGMF trades above its calculated fair value: price $9.96, fair value $3.01, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of REGMF?
No. The price is what the market pays today ($9.96); the fair value is what the company's own numbers justify ($3.01). For RemeGen Co. Ltd the two are $6.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is RemeGen Co. Ltd worth?
The market values RemeGen Co. Ltd at about $6.8B (market capitalisation, as of Sep 24, 2026). Per share that is $9.96; our models calculate a fair value of $3.01 per share.
What do the bullish and bearish scenarios say about REGMF?
Our models span a range for RemeGen Co. Ltd: cautious scenario $2.10, base $3.01, optimistic $7.77 per share (as of Sep 24, 2026, price $9.96). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of REGMF?
RemeGen Co. Ltd trades at a price-to-earnings ratio of 63.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.01 is built from several models across several years. Other multiples: P/B 12.6, P/S 13.5, EV/EBITDA 75.2.
How solid is the balance sheet of RemeGen Co. Ltd (REGMF)?
Balance-sheet figures for RemeGen Co. Ltd (as of Sep 24, 2026): return on equity 45.3%, debt of 0.20 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is REGMF from its 52-week high?
RemeGen Co. Ltd trades at $9.96, about 22% below its 52-week high of $12.85 and 97% above the low of $5.06 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $3.01 is for.
Which stocks are comparable to RemeGen Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RemeGen Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price $9.96, calculated fair value $3.01 (−70%), Quality Score 58/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of REGMF calculated?
We run RemeGen Co. Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.01, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. RemeGen Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RemeGen Co. Ltd (REGMF)?
The latest price we hold is from Sep 25, 2026 and stands at $9.96. Our model-based fair value is $3.01, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RemeGen Co. Ltd right now?
The price sits above even our optimistic bull case ($7.77). The favourable scenario is already priced in. The model range is unusually wide ($2.10 to $7.77). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of RemeGen Co. Ltd

How large is the market capitalisation of RemeGen Co. Ltd (REGMF)?
The market capitalisation of RemeGen Co. Ltd is $6.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RemeGen Co. Ltd (REGMF)?
The price-to-sales ratio of RemeGen Co. Ltd is 13.8 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RemeGen Co. Ltd (REGMF)?
Earnings per share at RemeGen Co. Ltd are $0.1900 (price ÷ EPS = P/E 63.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of RemeGen Co. Ltd (REGMF)?
The dividend yield of RemeGen Co. Ltd is 1.0% (payout 53.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of RemeGen Co. Ltd (REGMF)?
The net margin of RemeGen Co. Ltd is 21.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RemeGen Co. Ltd (REGMF)?
The return on equity (ROE) of RemeGen Co. Ltd is 45.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RemeGen Co. Ltd (REGMF)?
On an EBIT basis the return on assets of RemeGen Co. Ltd is −12.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of RemeGen Co. Ltd (REGMF)?
The operating margin of RemeGen Co. Ltd is −3.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at RemeGen Co. Ltd (REGMF)?
Revenue at RemeGen Co. Ltd is growing +24.8% versus a year earlier (3y avg +60.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does RemeGen Co. Ltd (REGMF) generate?
The free cash flow of RemeGen Co. Ltd is −140M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does RemeGen Co. Ltd (REGMF) carry?
The net debt of RemeGen Co. Ltd is 1.0B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch RemeGen Co. Ltd in the live analysis

One click puts RemeGen Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.